Topic: patent cliff

Top 10 drugs losing exclusivity in 2019

Pharma companies do their best to fight off patent expirations and generic competition as long as possible to protect their big moneymakers. But this year looks like the end of the line for many of the industry's top brands.

12. Amgen

It was a transitional year for Amgen: Demand for newer products Kyprolis, Prolia and Repatha just wasn’t enough to offset declines in some mature brands, including Enbrel, Neulasta and Epogen.